Lipogems To Launch Study to Treat Knee Osteoarthritis

Lipogems was granted unconditional approval by FDA to conduct an Investigational Device Exemption (IDE) study for the treatment of knee osteoarthritis (OA) compared to corticosteroids for a period of 12 months.

Lipogems is a market-stage medical device company that received FDA 510(k) clearance in 2014 for their device, which is used to process...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us